First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties

Objective Upacicalcet is a new renally excreted and injectable calcimimetic agent. We evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of single and multiple intravenous administration of upacicalcet in patients with secondary hyperparathyroidism undergoing hemodialysis. Methods This study was a multicenter, randomized, placebo-controlled, double-blinded, dose-escalation study consisting of a single-dose study and a multiple-dose study. The single-dose study consisted of seven dose steps from 0.025 to 0.8 mg. For each step, six patients were randomly assigned 2:1 to receive upacicalcet or a placebo. The multiple-dose study occurred over 3 weeks in three-dose steps from 0.05 to 0.2 mg. For each step, 12 patients were randomly assigned 3:1 to receive upacicalcet or a placebo. Results The plasma concentration of upacicalcet increased in a dose-dependent manner and was maintained for the next dialysis. Upacicalcet was approximately 80% removed by a single dialysis and did not increase in the plasma concentration with repeated administration. Serum intact parathyroid hormone and corrected calcium ($ Ca^{2+} $) levels tended to decrease in response to the plasma concentration of upacicalcet. In the single-dose study, upper gastrointestinal symptoms were observed as a non-serious and mild adverse drug reaction in the groups receiving upacicalcet ≥ 0.4 mg. In the multiple-dose study, abdominal discomfort occurred in each patient in the 0.1 mg and 0.2 mg groups. Conclusions Upacicalcet for patients with secondary hyperparathyroidism undergoing hemodialysis could be a calcimimetic agent that acts in a dose-dependent manner and persistently until the next dialysis session. No safety or tolerability issues specific to upacicalcet were found..

Medienart:	Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:61
Enthalten in:	Clinical pharmacokinetics - 61(2022), 9 vom: 28. Juni, Seite 1271-1284

Sprache:	Englisch

Beteiligte Personen:	Kazama, Junichiro James [VerfasserIn] Koiwa, Fumihiko [VerfasserIn] Yokoyama, Keitaro [VerfasserIn] Fukagawa, Masafumi [VerfasserIn] Asano, Kenji [VerfasserIn] Honda, Daisuke [VerfasserIn] Akizawa, Tadao [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

RVK:	RVK Klassifikation XA 36894

Anmerkungen:	© The Author(s) 2022

doi:	10.1007/s40262-022-01139-w

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2079467212